Real-world management of chronic myeloid leukemia in South Korea:the TARGET survey
- Author:
Jieun UHM
1
;
Kyoung Ha KIM
;
Hyewon LEE
;
Hawk KIM
;
Slader CASSANDRA
;
Inkyung JOO
;
Chul Won JUNG
Author Information
- Publication Type:ORIGINAL ARTICLE
- From:Blood Research 2021;56(1):31-37
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background:The global TARGET survey examined real-world management of chronic myeloid leukemia (CML) compared with international guideline recommendations. This report focused on the responses of physicians from South Korea compared with those of physicians from the rest of the world (ROW).
Methods:The self-administered, online survey, comprising 23 questions and clinical case scenarios, was completed between April and August 2017. It was designed to gather information on practicing physicians and local practices for CML diagnosis, disease monitoring, treatment, and adverse event (AE) management.
Results:While there were similarities in the mutation analysis and treatment efficacy between Korea and the ROW, there were also differences in CML management. Initial diagnostic testing was more comprehensive in Korea than in the ROW, and there was significantly better access to standardized polymerase chain reaction testing. Assessment of BCR-ABL levels during the first 12 months of treatment was excellent in Korea, and there was greater frontline use of second-generation BCR-ABL tyrosine kinase inhibitors. Korean physicians were significantly less likely to switch therapy for hematologic AEs. Treatment-free remission was not an important goal of therapy among Korean or ROW physicians.
Conclusion:This study identified some differences in the current CML management between Korea and the ROW; CML management in Korean patients was generally in line with the current guidelines.
